Continuation of the Phase II clinical trial of PRI-724 in fibrosis
First written in FY2024. 3 of 6 entries say "Advanced", first in FY2025-H1. Latest entry: 2026-10-14.
No other company in this theme has enough history to compare yet.
- FY2025AdvancedAnnual report
「Since April 2023, a Phase II clinical trial has been conducted at 38 sites in Japan in patients with decompensated cirrhosis caused by HCV, HBV, or MASH (metabolic dysfunction-associated steatohepatitis, formerly known as non-alcoholic steatohepatitis (NASH)). During the current fiscal year, enrollment was completed in the MASH cohort. The clinical trial is scheduled for completion in December 2027.」
Patient enrollment in the PRI-724 MASH cohort has been completed, and trial completion is scheduled for December 2027. - FY2025-H1AdvancedAnnual report
「In a Phase II clinical trial being conducted primarily at Tokyo Metropolitan Komagome Hospital in patients with cirrhosis caused by coinfection with HIV and HCV associated with hemophilia, patient enrollment ended in December 2024, and completion of the clinical trial is scheduled for December 2025.」
Patient enrollment in the PRI-724 Phase II clinical trial has ended, and the scheduled timing for trial completion has been stated. - FY2024First statedAnnual report
「From July 2023, the company added patients with decompensated cirrhosis caused by NASH (non-alcoholic steatohepatitis) to the study population and began a multicenter, placebo-controlled, randomized, double-blind comparative Phase II clinical trial.」
The company reports significant improvements in liver stiffness, hepatic reserve, and serum albumin levels in Phase I and Phase IIa trials involving patients with cirrhosis.